Usage Examples
- The BLA goes to CBER, not CDER, because the product is an AAV gene therapy.
- We cannot reference the CDMO's master file in the BLA, so module 3 has to carry the full process description.
- Filing is expected in September, which puts the PDUFA goal date in July next year.
What is Biologics License Application (BLA)?
A Biologics License Application (BLA) is the marketing application a manufacturer submits to obtain an FDA license under section 351 of the Public Health Service Act, granted on a demonstration that the biological product is safe, pure, and potent.
A Biologics License Application exists because a biological product cannot be verified by structure alone. Biological products are derived from living material, complex in structure, and usually not fully characterized, so the statute licenses the manufacturer, the process, and the facility rather than only the molecule. No biological product may enter interstate commerce unless a biologics license is in effect for it.
A Biologics License Application covers products licensed under section 351 of the PHS Act: vaccines, blood components, allergenics, cells, tissues, gene therapies, monoclonal antibodies, and most therapeutic proteins. A Biologics License Application does not cover chemically synthesized small-molecule drugs, which are approved in an NDA under FD&C Act section 505. Product class, not sponsor preference, decides whether CBER or CDER reviews it.
A Biologics License Application is filed on Form FDA 356h, in eCTD format, through the FDA Electronic Submission Gateway, with a FY 2026 PDUFA application fee of $4,682,003 where clinical data are required. FDA aims to act within 10 months of filing, or 6 months under priority review, and licensure also turns on the facility, which the applicant must consent to have inspected.
Not to be confused with
- NDA
- an NDA is approved under FD&C Act section 505; a BLA is licensed under PHS Act section 351 and the approval issues a US license number. Since 23 March 2020 approved NDAs for biological products, including insulins and human growth hormone, were deemed to be BLAs, so the pathway follows the product's statutory category, not its filing history.
- Biosimilar application
- a biosimilar is submitted under section 351(k), which is still a BLA but relies on a licensed reference product instead of a standalone safety and efficacy package. An unqualified "BLA" normally means a standalone 351(a) application.
- IND
- an IND authorizes human study of an unlicensed biological product; a BLA requests permission to market it. The IND generates the nonclinical and clinical data the BLA later relies on, and the two are separate applications with separate numbers.
- eCTD
- eCTD is the electronic format the BLA must be delivered in, not the application itself. A technically valid eCTD package can still carry a BLA that FDA refuses to file.
A BLA is governed by section 351 of the PHS Act, the FD&C Act, and 21 CFR parts 600 through 680. These are the obligations that decide whether it gets filed and stays licensed.
What you must do
- 1Submit the application to the Director of CBER or CDER on the prescribed forms, with data from nonclinical laboratory and clinical studies demonstrating safety, purity, and potency; FDA does not treat the application as filed until all pertinent information and data have been received21 CFR 601.2(a)
- 2Carry all drug substance, drug substance intermediate, and drug product information inside the BLA itself, because a BLA may not incorporate that information by reference from a master file21 CFR 601.2(g)(1)
- 3Consent to inspection of the facility named in the application, and show that the facility meets standards designed to assure the product continues to be safe, pure, and potent42 U.S.C. 262(a)(2)(C)
- 4Submit the BLA, and every later amendment, supplement, and report, in eCTD format to CDER or CBERFDA eCTD requirement (CDER/CBER)
- 5After licensure, obtain FDA approval of a prior-approval supplement before distributing product made using any change with substantial potential to adversely affect identity, strength, quality, purity, or potency21 CFR 601.12(b)
Common mistakes
Building the CMC section around a supplier's master file
21 CFR 601.2(g)(1) bars a BLA from incorporating drug substance, drug substance intermediate, or drug product information by reference from a master file. Teams that plan a BLA the way they would plan an NDA find out late that the contract manufacturer has to hand over full process and control detail, and a letter of authorization does not fix it. The renegotiation lands in the worst weeks of the timeline.
Treating the submission date as the start of the review clock
the PDUFA goals run from the filing date, and 21 CFR 601.2(a) states that an application is not considered filed until all pertinent information and data have been received. Board and investor timelines built off the submission date are wrong by roughly one quarter before a single deficiency is raised.
Assuming a legacy protein product still sits under an NDA
on 23 March 2020 the BPCI Act deemed approved section 505 applications for biological products to be licenses under section 351, and the Further Consolidated Appropriations Act, 2020 removed the chemically-synthesized-polypeptide carve-out from the definition of a protein. Lifecycle submissions for those products follow 21 CFR 601.12, not 21 CFR 314.70.
When This Matters
- The BLA goes to CBER, not CDER, because the product is an AAV gene therapy.
- We cannot reference the CDMO's master file in the BLA, so module 3 has to carry the full process description.
- Filing is expected in September, which puts the PDUFA goal date in July next year.
Frequently Asked Questions
A BLA is licensed under section 351 of the Public Health Service Act; an NDA is approved under section 505 of the FD&C Act. The BLA standard is safe, pure, and potent, and approval issues a biologics license carrying a US license number that must appear on the labeling. Both use Form FDA 356h.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
Related Regulatory Intelligence
Related Actions
Sources & References
- 21 CFR 601.2 - Applications for biologics licenses; procedures for filing
- 42 U.S.C. 262 - Regulation of biological products
- FDA - Biologics License Applications (BLAs) for CBER-Regulated Products
- FDA - Deemed to be a License Provision of the BPCI Act
- FDA - Prescription Drug User Fee Amendments (PDUFA) fee rates
